Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy.
Background:Serum carbohydrate antigen 19-9 (CA 19-9) has been shown to be a sensitive and specific serum marker for pancreatic cancer. Little has been published about correlations between baseline CA 19-9 level or changes to CA 19-9 level and median overall survival (mOS). Its impact on monitoring t...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00155/full |
id |
doaj-30ddd783245242ea89cd2da76ff49c3a |
---|---|
record_format |
Article |
spelling |
doaj-30ddd783245242ea89cd2da76ff49c3a2020-11-25T01:07:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2013-06-01310.3389/fonc.2013.0015552319Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy.Uwe ePelzer0Andreas eHilbig1Jens eStieler2Marianne eSinn3Marcus eBahra4Bernd eDörken5Hanno eRiess6Universitätsmedizin Berlin - Charité, Comprehensive Cancer CenterUniversitätsmedizin Berlin - Charité, Comprehensive Cancer CenterUniversitätsmedizin Berlin - Charité, Comprehensive Cancer CenterUniversitätsmedizin Berlin - Charité, Comprehensive Cancer CenterUniversitätsmedizin Berlin - CharitéUniversitätsmedizin Berlin - Charité, Comprehensive Cancer CenterUniversitätsmedizin Berlin - Charité, Comprehensive Cancer CenterBackground:Serum carbohydrate antigen 19-9 (CA 19-9) has been shown to be a sensitive and specific serum marker for pancreatic cancer. Little has been published about correlations between baseline CA 19-9 level or changes to CA 19-9 level and median overall survival (mOS). Its impact on monitoring treatment efficacy remains under discussion, however.Methods:CA 19-9 serum level was measured in 181 consecutive patients with advanced pancreatic cancer (APC) being treated with gemcitabine-based first line chemotherapy. We separated the patients into several groups depending on baseline CA 19-9 levels and the CA 19-9 response after 6 to 8 weeks of treatment. Evaluations were made using SPSS 19.9.Results:Median baseline CA 19-9 level was 1,493 U/ml (range 40-1,043,301). Patients with baseline CA 19-9 ≤1,000 U/ml had a mOS of 14.9 months [95%CI: 11.36:18.44], whereas patients with CA 19-9 >1,000 U/ml had a mOS of 7.4 months ([95%CI: 5.93:8.87] p<0.001, HR 2.12). With regard to the change in CA 19-9 after 6 to 8 weeks of treatment: patients with increased CA 19-9 levels had a mOS of 8.1 months, those with stabilized CA 19-9 levels 11.6 months, and those with decreased CA 19-9 levels 11.1 months (p<0.019).Conclusions:CA 19-9 levels can separate patients with differing mortality risks at baseline. Patients with stabilization or high response of CA 19-9 after 6 to 8 weeks of treatment had no significant differences in survival rates, whereas patients with increased CA 19-9 had significantly lower survival rates, indicating an early treatment failure.http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00155/fullPancreatic NeoplasmspredictionresponseCA 19-9therapy control |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Uwe ePelzer Andreas eHilbig Jens eStieler Marianne eSinn Marcus eBahra Bernd eDörken Hanno eRiess |
spellingShingle |
Uwe ePelzer Andreas eHilbig Jens eStieler Marianne eSinn Marcus eBahra Bernd eDörken Hanno eRiess Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy. Frontiers in Oncology Pancreatic Neoplasms prediction response CA 19-9 therapy control |
author_facet |
Uwe ePelzer Andreas eHilbig Jens eStieler Marianne eSinn Marcus eBahra Bernd eDörken Hanno eRiess |
author_sort |
Uwe ePelzer |
title |
Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy. |
title_short |
Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy. |
title_full |
Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy. |
title_fullStr |
Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy. |
title_full_unstemmed |
Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy. |
title_sort |
value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first line therapy. |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2013-06-01 |
description |
Background:Serum carbohydrate antigen 19-9 (CA 19-9) has been shown to be a sensitive and specific serum marker for pancreatic cancer. Little has been published about correlations between baseline CA 19-9 level or changes to CA 19-9 level and median overall survival (mOS). Its impact on monitoring treatment efficacy remains under discussion, however.Methods:CA 19-9 serum level was measured in 181 consecutive patients with advanced pancreatic cancer (APC) being treated with gemcitabine-based first line chemotherapy. We separated the patients into several groups depending on baseline CA 19-9 levels and the CA 19-9 response after 6 to 8 weeks of treatment. Evaluations were made using SPSS 19.9.Results:Median baseline CA 19-9 level was 1,493 U/ml (range 40-1,043,301). Patients with baseline CA 19-9 ≤1,000 U/ml had a mOS of 14.9 months [95%CI: 11.36:18.44], whereas patients with CA 19-9 >1,000 U/ml had a mOS of 7.4 months ([95%CI: 5.93:8.87] p<0.001, HR 2.12). With regard to the change in CA 19-9 after 6 to 8 weeks of treatment: patients with increased CA 19-9 levels had a mOS of 8.1 months, those with stabilized CA 19-9 levels 11.6 months, and those with decreased CA 19-9 levels 11.1 months (p<0.019).Conclusions:CA 19-9 levels can separate patients with differing mortality risks at baseline. Patients with stabilization or high response of CA 19-9 after 6 to 8 weeks of treatment had no significant differences in survival rates, whereas patients with increased CA 19-9 had significantly lower survival rates, indicating an early treatment failure. |
topic |
Pancreatic Neoplasms prediction response CA 19-9 therapy control |
url |
http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00155/full |
work_keys_str_mv |
AT uweepelzer valueofcarbohydrateantigen199inpredictingresponseandtherapycontrolinpatientswithmetastaticpancreaticcancerundergoingfirstlinetherapy AT andreasehilbig valueofcarbohydrateantigen199inpredictingresponseandtherapycontrolinpatientswithmetastaticpancreaticcancerundergoingfirstlinetherapy AT jensestieler valueofcarbohydrateantigen199inpredictingresponseandtherapycontrolinpatientswithmetastaticpancreaticcancerundergoingfirstlinetherapy AT marianneesinn valueofcarbohydrateantigen199inpredictingresponseandtherapycontrolinpatientswithmetastaticpancreaticcancerundergoingfirstlinetherapy AT marcusebahra valueofcarbohydrateantigen199inpredictingresponseandtherapycontrolinpatientswithmetastaticpancreaticcancerundergoingfirstlinetherapy AT berndedorken valueofcarbohydrateantigen199inpredictingresponseandtherapycontrolinpatientswithmetastaticpancreaticcancerundergoingfirstlinetherapy AT hannoeriess valueofcarbohydrateantigen199inpredictingresponseandtherapycontrolinpatientswithmetastaticpancreaticcancerundergoingfirstlinetherapy |
_version_ |
1725186673838391296 |